Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

URL https://www.businesswire.com/news/home/2021030800
Sourcebusinesswire
Date Published03/08/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Moderna Inc.
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:Both
City reshored to:Bloomington
State(s) reshored to:IN
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredCOVID-19 Vaccine, RNA (mRNA) therapeutics
What domestic positive factors made reshoring more attractive?Skilled workforce availability/training, Under-utilized capacity, Other, Covid-19, import replacement
Find Reshoring Articles